Literature DB >> 33173379

Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations.

R Foley1, R Kaedbey2, K Song3, C P Venner4, D White5, S Doucette6, A Christofides6, D E Reece7.   

Abstract

The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that patients with multiple myeloma are at increased risk of covid-19 infection and related complications, national bodies and experts around the globe have made recommendations for risk mitigation strategies for those vulnerable patients. Understandably, because of the novelty of the virus, many of the proposed risk mitigation strategies have thus far been reactionary and cannot be supported by strong evidence. In this editorial, we highlight some of the risk mitigation strategies implemented at our institutions across Canada during the first wave of covid-19, and we discuss the considerations that should be made when managing patients during the second wave and beyond. 2020 Multimed Inc.

Entities:  

Keywords:  Coronavirus; covid-19; multiple myeloma

Mesh:

Year:  2020        PMID: 33173379      PMCID: PMC7606044          DOI: 10.3747/co.27.7149

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  8 in total

1.  High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.

Authors:  Tania Jain; Mohamad Bassam Sonbol; Belal Firwana; Kantha R Kolla; Diana Almader-Douglas; Jeanne Palmer; Rafael Fonseca
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-20       Impact factor: 5.742

2.  Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.

Authors:  Mukul Aggarwal; Narendra Agrawal; Neha Yadav; Priyanka Verma; Rayaz Ahmed; Pallavi Mehta; Jyotsna Kapoor; Dinesh Bhurani
Journal:  Ann Hematol       Date:  2018-05-21       Impact factor: 3.673

3.  Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Shaji K Kumar; Francis K Buadi; David Dingli; Angela Dispenzieri; Suzanne R Hayman; William J Hogan; Prashant Kapoor; Martha Q Lacy; Nelson Leung; Rahma Warsame; Taxiarchis Kourelis; Wilson Gonsalves; Morie A Gertz
Journal:  Br J Haematol       Date:  2018-04-29       Impact factor: 6.998

4.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

5.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Authors:  Andrew L Himelstein; Jared C Foster; James L Khatcheressian; John D Roberts; Drew K Seisler; Paul J Novotny; Rui Qin; Ronald S Go; Stephen S Grubbs; Tracey O'Connor; Mario R Velasco; Douglas Weckstein; Ann O'Mara; Charles L Loprinzi; Charles L Shapiro
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

6.  Management of multiple myeloma during COVID-19 pandemic.

Authors:  Y S Jethava; Rafael Fonseca; Ola Landgren
Journal:  Leuk Res Rep       Date:  2020-06-13

7.  Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.

Authors:  Gordon Cook; A John Ashcroft; Guy Pratt; Rakesh Popat; Karthik Ramasamy; Martin Kaiser; Matthew Jenner; Sarah Henshaw; Rachel Hall; Jonathan Sive; Simon Stern; Matthew Streetly; Ceri Bygrave; Richard Soutar; Neil Rabin; Graham H Jackson
Journal:  Br J Haematol       Date:  2020-06-10       Impact factor: 8.615

Review 8.  Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).

Authors:  Evangelos Terpos; Monika Engelhardt; Gordon Cook; Francesca Gay; Maria-Victoria Mateos; Ioannis Ntanasis-Stathopoulos; Niels W C J van de Donk; Hervé Avet-Loiseau; Roman Hajek; Annette Juul Vangsted; Heinz Ludwig; Sonja Zweegman; Philippe Moreau; Hermann Einsele; Mario Boccadoro; Jesus San Miguel; Meletios A Dimopoulos; Pieter Sonneveld
Journal:  Leukemia       Date:  2020-05-22       Impact factor: 12.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.